Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism Academic Article uri icon

Overview

MeSH Major

  • Glucose
  • Glutamine
  • Metformin
  • Prostatic Neoplasms

abstract

  • Metformin inhibits cancer cell proliferation, and epidemiology studies suggest an association with increased survival in patients with cancer taking metformin; however, the mechanism by which metformin improves cancer outcomes remains controversial. To explore how metformin might directly affect cancer cells, we analyzed how metformin altered the metabolism of prostate cancer cells and tumors. We found that metformin decreased glucose oxidation and increased dependency on reductive glutamine metabolism in both cancer cell lines and in a mouse model of prostate cancer. Inhibition of glutamine anaplerosis in the presence of metformin further attenuated proliferation, whereas increasing glutamine metabolism rescued the proliferative defect induced by metformin. These data suggest that interfering with glutamine may synergize with metformin to improve outcomes in patients with prostate cancer.

publication date

  • July 15, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3930683

Digital Object Identifier (DOI)

  • 10.1158/0008-5472.CAN-13-0080

PubMed ID

  • 23687346

Additional Document Info

start page

  • 4429

end page

  • 38

volume

  • 73

number

  • 14